Sila Realty Trust, Inc. (SILA) 주식 분석

회사 개요

Sila Realty Trust, Inc. is a specialized real estate entity that has elected to be taxed as a real estate investment trust, or REIT, under the Internal Revenue Code of 1986, focusing primarily on investing in high-quality net lease healthcare facilities. This company operates within the Real Estate sector, specifically the REIT - Healthcare Facilities industry, which positions it to benefit from long-term lease agreements with medical providers while adhering to strict regulatory tax structures. The enterprise currently maintains a market capitalization of $1.34B and employs a workforce of 47 individuals to manage its extensive portfolio of medical properties. These financial figures, particularly the market cap relative to its annual revenue of $197.54M, indicate a mid-cap status where the valuation is heavily influenced by asset quality and lease stability rather than traditional enterprise scaling dynamics typical of larger industrial REITs.

재무 건전성

The company reported a trailing twelve-month revenue of $197.54M and generated a net income of $32.95M, while reporting an EBITDA of $152.85M. The significant gap between the EBITDA of $152.85M and the net income of $32.95M reveals a substantial cost structure driven by interest expenses, depreciation, and amortization, which are characteristic of capital-intensive real estate businesses. Sila Realty Trust generated free cash flow of $87.48M, demonstrating a robust ability to convert earnings into cash that can be utilized for debt servicing, capital expenditures, or returning capital to shareholders. However, the total debt stands at $719.14M against a cash balance of $35.20M, resulting in a debt-to-equity ratio of 54.02, which indicates a highly leveraged balance sheet common in the REIT sector. Despite the leverage, the current ratio of 5.10 suggests a strong liquidity position capable of meeting short-term obligations with ease. Return on Equity stands at 2.4% and Return on Assets is 2.3%, metrics that reflect the capital efficiency of management in generating returns relative to the equity base and total assets employed.

밸류에이션 평가

The stock carries a trailing P/E ratio of 40.37, while a forward P/E is not available in current data, implying that future earnings estimates are either undefined or significantly different from historical performance. The price-to-book ratio is 1.00, indicating that the market values the company's equity at par with its book value, suggesting no significant premium or discount relative to the underlying asset values. Alternative valuation metrics include a price-to-sales ratio of 6.77 and an EV/EBITDA of 13.23, which suggest the market is pricing the stock based on revenue generation and operational cash flow potential despite the lack of forward earnings guidance. The 52-week trading range spans from a low of $21.94 to a high of $26.88, providing a context for current price volatility within the recent fiscal year. The beta value of 0.14 indicates that the stock's price volatility is significantly lower than the broader market, reflecting the defensive nature of healthcare real estate assets.

Growth & Income

Revenue growth year-over-year stands at 8.9%, whereas earnings growth year-over-year is -56.4%, revealing a scenario where earnings are shrinking at a much faster rate than revenue, likely due to the aforementioned high leverage and interest cost impacts. The company offers a dividend yield of 6.6%, but the payout ratio is 266.7%, which indicates that the dividend is being funded from sources other than current net income, such as retained earnings or cash reserves, rather than sustainable earnings distribution. This high payout ratio suggests that the dividend sustainability is currently dependent on the company's cash flow generation and asset liquidation potential rather than operational profitability alone. Overall, the growth and income profile presents a trade-off between attractive current income yields and significant earnings contraction, requiring careful analysis of the balance sheet strength to assess long-term viability.